Aseptika selected for Discovery Start-Ups 2014 award

Aseptika Limited was selected as one of five winners out of the eighteen strong field of UK start-up companies pitching for the winning prizes at the Discovery Start-Ups 2014 event held on Wednesday, 22^nd October at Deloitte’s in London.

In its 5^th year the Discovery Start-Ups 2014 competition, organised by Cambridge Wireless and SETsquared Partnership, attracted its strongest field yet with 80 competition applicants. Of the entrants, 18 start-ups were selected to pitch to a strong panel of technology senior executive judges that deliberated and quizzed the entrepreneurs to assess their technology, its protection, business models and financing position in the fast moving wireless and mobile markets.

Discovery Start-up 2014 organisers, sponsors and winners, Kevin A. Auton, Ph.D., Co-Founder and Managing Director of Aseptika Limited (Activ8rlives) is located in centre front row position.

Aseptika is a healthcare company developing a self-monitoring service in the form of a home-use sputum test, simple self-monitoring devices and an online user interface known as Activ8rlives. Their niche focus is predicting the onset of lung infections in people with long-term respiratory conditions. Patients with severe airway disease are often chronically infected by the bacterium Pseudomonas aeruginosa and in these patients, despite attempts to treat these infections, complete eradication can be difficult. Flare-ups of the infection (exacerbations) are common, leading to deterioration in symptoms, which can result in 3-4 prolonged hospital admissions per year. Repeated exacerbations result in loss of lung function reducing quality of life, are very disruptive, costly and can result in premature death.

Commenting on the win Kevin Auton, Ph.D., Co-Founder and Managing Director of Aseptika Limited commented:

We are delighted to be awarded this honour, especially in light of the outstanding quality of the finalists that presented to the Judges on the day. As a healthcare company we utilise wireless technology, cloud computing, connected and wearable devices, combined with a biomarker test still in development. We are working towards helping to empower patients, their family or carers to monitor for declining health in elderly or vulnerable members of the family.

Kevin added further: “Our ultimate vision and mission is to provide tools for lung disease patients, to do what has been done for diabetics with home blood glucose tests.”